A Phase II, Randomised, Double-Blind, Placebo-controlled Study To Investigate The Effects Of ZD1839 (IRESSA) [gefitinib] On Cell Proliferation In Oestrogen And Progesterone Receptor Negative Breast Cancer Prior To Surgery.

Trial Profile

A Phase II, Randomised, Double-Blind, Placebo-controlled Study To Investigate The Effects Of ZD1839 (IRESSA) [gefitinib] On Cell Proliferation In Oestrogen And Progesterone Receptor Negative Breast Cancer Prior To Surgery.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2011

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jan 2011 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 10 Jan 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top